Declining Public Health Burden of Digoxin Toxicity From 1991 to 2004

We hypothesized that digoxin toxicity has declined in recent years, and that the decline is accompanied by reductions in overall utilization and dose. To analyze trends in digoxin toxicity and utilization from 1991 to 2004, we used surveys from the National Center for Health Statistics and Medicaid...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2008-07, Vol.84 (1), p.90-94
Main Authors: Haynes, K, Heitjan, DF, Kanetsky, PA, Hennessy, S
Format: Article
Language:English
Subjects:
Ambulatory Care - trends
Biological and medical sciences
Databases, Factual - trends
Digoxin - adverse effects
Digoxin - poisoning
Digoxin - therapeutic use
Drug-Related Side Effects and Adverse Reactions
Hospitalization - trends
Humans
Medical sciences
Pharmacology. Drug treatments
Public Health - trends
United Kingdom - epidemiology
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We hypothesized that digoxin toxicity has declined in recent years, and that the decline is accompanied by reductions in overall utilization and dose. To analyze trends in digoxin toxicity and utilization from 1991 to 2004, we used surveys from the National Center for Health Statistics and Medicaid data in the United States and The Health Improvement Network (THIN) database in the United Kingdom. There was a significant decline in digoxin toxicity hospitalizations in the United States and a decline in ambulatory digoxin toxicity in the United Kingdom. The study demonstrated a reduction in the use of digoxin in the United States, but found no change in digoxin use in the United Kingdom. Finally, the number of prescriptions written for at least 250 μg decreased in the United States and the United Kingdom. The public health burden of digoxin toxicity declined dramatically from 1991 to 2004 in the United Kingdom and the United States. Clinical Pharmacology & Therapeutics (2008); 84, 1, 90–94 doi:10.1038/sj.clpt.6100458
ISSN:0009-9236
1532-6535
DOI:10.1038/sj.clpt.6100458